Under the 2019 grant program for paediatric drug formulations for poverty-related diseases, the MiniMox consortium has received €2.1M from the Second European and Developing Countries Clinical Trials Partnership (EDCTP2) programme and €724,000 from the Luxembourg National Research Fund (LNRF) to co‑fund the development of the new formulation. Medicines Development for Global Health (MDGH) will fund the bench-top development work, GMP-grade manufacturing of a selected formulation for the clinical trial and development of an enhanced population pharmacokinetic model of moxidectin in children and adults.

The opinions expressed and arguments employed on this website do not necessarily reflect the official views of the EDCTP or LNRF. Neither the EDCTP/LNRF nor any person acting on behalf of the EDCTP/LNRF is responsible for the use which might be made of the information provided on this website.